The Chinese State Intellectual Property Office (SIPO) has revoked a patent covering biopharmaceutical company Gilead Science’s HIV drug Viread, Reuters subsidiary news site BioWorld reported.
On August 8 the IPAB revoked another patent owned by a Western pharmaceutical company – this time related to Allergan’s eye drug Combigan.
Ambry Genetics, the laboratory sued last month by biotech company Myriad over patents covering the BRCA1 and BRCA2 genes, has hit back with antitrust claims.
The Kolkata Patent Office has refused divisional patents related to Swiss pharmaceutical company Roche’s breast cancer drug Herceptin.
Eversheds has appointed the former head of Sidley Austin's London IP and life sciences team Brett Rowland, as a partner.
On August 5, Swiss pharmaceutical company Roche signed an agreement with the MPP to increase access to its drug valganciclovir (Valcyte), an oral medicine for the treatment of preventable viral infection cytomegalovirus (CMV).
India’s Intellectual Property Appeal Board has revoked a patent covering GlaxoSmithKline’s breast cancer drug Tykerb, in the latest blow to western pharmaceutical companies in India.
The Intellectual Property Appellate Board in Chennai has cancelled two trademarks associated with versions of Viagra.
The Court of Appeal for England and Wales has upheld the Patent Court’s decision that Teva Pharmaceutical Industries’ UK patent 762,888, relating to the multiple sclerosis drug Copaxone, is valid.
A US court has ruled that an Israeli company’s patent for a multiple sclerosis (MS) drug is invalid, paving the way for rivals to market a generic version.